Contradictory results with high-dosage rifamycin in mice and humans
- PMID: 23341429
- PMCID: PMC3553725
- DOI: 10.1128/AAC.01705-12
Contradictory results with high-dosage rifamycin in mice and humans
Comment in
-
Reply to "Contradictory results with high-dosage rifamycin in mice and humans".Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. Antimicrob Agents Chemother. 2013. PMID: 23341430 Free PMC article. No abstract available.
Comment on
-
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4. Antimicrob Agents Chemother. 2012. PMID: 22664964 Free PMC article.
References
-
- Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset J, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344 doi:10.1371/journal.pmed.0040344 - DOI - PMC - PubMed
-
- Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, Tuberculosis Trials Consortium 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium. J. Infect. Dis. 206:1030–1040 - PubMed
-
- Mitchison DA. 2012. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Int. J. Tuberc. Lung Dis. 16:1186–1189 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
